Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

about

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review

P2860

Q54982000-5078407E-1429-48A4-8FAA-3FF99D330DF9 Q58802067-11F4E0B2-7BE5-49D3-820D-61993093DCD4

P2860

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q40189187

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Long-term outcomes of tyrosine ...... tastatic renal cell carcinoma.

@en

type

Item

label

Long-term outcomes of tyrosine ...... tastatic renal cell carcinoma.

@en

prefLabel

Long-term outcomes of tyrosine ...... tastatic renal cell carcinoma.

@en

P1476

Long-term outcomes of tyrosine ...... tastatic renal cell carcinoma.

@en

P2093

Bumsik Hong

http://www.w3.org/2001/XMLSchema#string

Cheryn Song

http://www.w3.org/2001/XMLSchema#string

Dae-Ho Lee

http://www.w3.org/2001/XMLSchema#string

Dalsan You

http://www.w3.org/2001/XMLSchema#string

Hanjong Ahn

http://www.w3.org/2001/XMLSchema#string

In-Gab Jeong

http://www.w3.org/2001/XMLSchema#string

Inkeun Park

http://www.w3.org/2001/XMLSchema#string

Jae-Lyun Lee

http://www.w3.org/2001/XMLSchema#string

Jin-Hee Ahn

http://www.w3.org/2001/XMLSchema#string

Jun Hyuk Hong

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic rena

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.

P2888

s00280-015-2942-1

P304

339-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2942-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dong-Hoe Koo

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1006314103

http://www.w3.org/2001/XMLSchema#string

P698

26687171

http://www.w3.org/2001/XMLSchema#string

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

about

P2860

P2860

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698